NCT07270666

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

Pragmatic Pilot Study of ctDNA Informed Immune Checkpoint Inhibitor De-escalation in Advanced/Recurrent Mismatch Repair Deficient (MMR-D)/Microsatellite Instability High (MSI-H) Endometrial Cancer Using Standard of Care Treatments

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair deficient (MMR-D) gene or microsatellite instability high (MSI-H) gene. The researchers will see how doctors and their patients use the results of ctDNA testing after 1 year of standard chemotherapy and immune checkpoint inhibitor (ICI) treatment to decide whether to continue maintenance ICI treatment past 1 year. The researchers will also look at the health outcomes of people in this study (for example, whether they are cancer free at the end of their participation in the study).

Conditions

• Endometrial Cancer

Interventions

Type	Name	Description
GENETIC	ctDNA Testing	Patients will undergo ctDNA sampling at the 1-year timepoint using the commercially available Natera SignateraTM test.
OTHER	Blood draw	at the 1-year timepoint

Timeline

• Start date: 2025-11-25
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2025-12-08
• Last updated: 2025-12-18

Locations

7 sites across 1 country: United States